Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. (Nasdaq: DNTH) is a clinical-stage biotechnology company developing therapies for severe autoimmune diseases. Its lead candidate, claseprubart, is a monoclonal antibody designed to selectively inhibit active C1s in the classical complement pathway; it is being evaluated for generalized… From the company’s description.
In fiscal 2025, Dianthus Therapeutics, Inc. reported revenue of $2.04M, down 67.3% from fiscal 2024, and a net loss of $162.34M. Its operating margin was −8739.3%, and operations used $129.06M in cash. Over the twelve months to Jun 30, 2026, revenue was $1.90M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Dianthus Therapeutics, Inc. does
In the company’s own words
Dianthus Therapeutics, Inc. (Nasdaq: DNTH) is a clinical-stage biotechnology company developing therapies for severe autoimmune diseases. Its lead candidate, claseprubart, is a monoclonal antibody designed to selectively inhibit active C1s in the classical complement pathway; it is being evaluated for generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Its second clinical-stage candidate, DNTH212, is a bifunctional fusion protein designed to target BDCA2 and inhibit BAFF/APRIL, addressing pathways involved in innate and adaptive immune responses. The company’s research and development pipeline is its central business, and it does not have a commercial organization for marketing, sales or distribution. It holds development and commercialization rights outside Greater China, while partners hold rights in Greater China for its candidates. In 2025, Dianthus reported positive Phase 2 results for claseprubart in myasthenia gravis and initiated a Phase 1 study of DNTH212 in China. The company resulted from a 2023 business combination with Dianthus Therapeutics OpCo, Inc.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1690585
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Dianthus Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Dianthus Therapeutics, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Dianthus Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Dianthus Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Dianthus Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Dianthus Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”